{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:11:06Z","timestamp":1770819066828,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Childs Nerv Syst"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00381-025-07084-w","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T20:10:07Z","timestamp":1766347807000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Significant clinical and radiologic response to targeted therapy in pediatric cervicomedullary low-grade gliomas harboring the BRAFV600E mutation"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7946-8081","authenticated-orcid":false,"given":"G. Abebe","family":"Campino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Shrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Constantini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Toren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lurye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Yalon-Oren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,21]]},"reference":[{"issue":"6","key":"7084_CR1","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1093\/neuonc\/nox031","volume":"19","author":"RJ Packer","year":"2017","unstructured":"Packer RJ, Pfister S, Bouffet E (2017) Pediatric low-grade gliomas: implications of the biologic era. Neuro Oncol 19(6):750\u2013761. https:\/\/doi.org\/10.1093\/neuonc\/nox031","journal-title":"Neuro Oncol"},{"issue":"5","key":"7084_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3171\/jns.1997.86.5.0747","volume":"86","author":"RJ Packer","year":"1997","unstructured":"Packer RJ, Ater J, Allen J (1997) Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 86(5):747\u2013754. https:\/\/doi.org\/10.3171\/jns.1997.86.5.0747","journal-title":"J Neurosurg"},{"issue":"34","key":"7084_CR3","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1200\/JCO.2016.67.4609","volume":"34","author":"A Lassaletta","year":"2016","unstructured":"Lassaletta A, Scheinemann K, Zelcer SM et al (2016) Phase II weekly vinblastine for chemotherapy-naive children with progressive low-grade glioma: a Canadian Pediatric Brain Tumor Consortium study. J Clin Oncol 34(34):3537\u20133543. https:\/\/doi.org\/10.1200\/JCO.2016.67.4609","journal-title":"J Clin Oncol"},{"issue":"22","key":"7084_CR4","doi-asserted-by":"publisher","first-page":"3598","DOI":"10.1200\/JCO.2008.20.8104","volume":"27","author":"TE Merchant","year":"2009","unstructured":"Merchant TE, Kun LE, Wu S et al (2009) Phase II trial of conformal radiation therapy for pediatric low-grade glioma. J Clin Oncol 27(22):3598\u20133604. https:\/\/doi.org\/10.1200\/JCO.2008.20.8104","journal-title":"J Clin Oncol"},{"issue":"4","key":"7084_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.ijrobp.2018.11.032","volume":"103","author":"JM Cherlow","year":"2019","unstructured":"Cherlow JM, Shaw DWW, Margraf LR et al (2019) Conformal radiation therapy for pediatric patients with low-grade glioma: results from the Children\u2019s Oncology Group phase 2 study ACNS0221. Int J Radiat Oncol Biol Phys 103(4):861\u2013868. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.11.032","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"7084_CR6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","volume":"121","author":"G Schindler","year":"2011","unstructured":"Schindler G, Capper D, Meyer J et al (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma, and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121(3):397\u2013405. https:\/\/doi.org\/10.1007\/s00401-011-0802-6","journal-title":"Acta Neuropathol"},{"issue":"27","key":"7084_CR7","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1200\/JCO.2014.59.9215","volume":"33","author":"A Gajjar","year":"2015","unstructured":"Gajjar A, Bowers DC, Karajannis MA et al (2015) Pediatric brain tumors: innovative genomic information is transforming the diagnostic and clinical landscape. J Clin Oncol 33(27):2986\u20132998. https:\/\/doi.org\/10.1200\/JCO.2014.59.9215","journal-title":"J Clin Oncol"},{"issue":"25","key":"7084_CR8","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.1200\/JCO.2016.71.8726","volume":"35","author":"A Lassaletta","year":"2017","unstructured":"Lassaletta A, Zapotocky M, Mistry M et al (2017) Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol 35(25):2934\u20132941. https:\/\/doi.org\/10.1200\/JCO.2016.71.8726","journal-title":"J Clin Oncol"},{"issue":"4","key":"7084_CR9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3171\/2015.3.PEDS14591","volume":"16","author":"JH McAbee","year":"2015","unstructured":"McAbee JH, Modica J, Thompson CJ et al (2015) Cervicomedullary tumors in children. J Neurosurg Pediatr 16(4):357\u2013366. https:\/\/doi.org\/10.3171\/2015.3.PEDS14591","journal-title":"J Neurosurg Pediatr"},{"key":"7084_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000121220","volume":"27","author":"LA Quires","year":"1997","unstructured":"Quires LA, Constantini S, Miller DC, Epstein F (1997) Diffuse infiltrating astrocytoma of the cervicomedullary region: clinicopathologic entity. Pediatr Neurosurg 27:153\u2013159. https:\/\/doi.org\/10.1159\/000121220","journal-title":"Pediatr Neurosurg"},{"key":"7084_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3171\/jns.1987.67.4.0483","volume":"67","author":"F Epstein","year":"1987","unstructured":"Epstein F, Wisoff J (1987) Intra-axial tumors of the cervicomedullary junction. J Neurosurg 67:483\u2013487. https:\/\/doi.org\/10.3171\/jns.1987.67.4.0483","journal-title":"J Neurosurg"},{"key":"7084_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000121208","volume":"27","author":"HL Weiner","year":"1997","unstructured":"Weiner HL, Freed D, Woo HH et al (1997) Intra-axial tumors of the cervicomedullary junction: surgical results and long-term outcome. Pediatr Neurosurg 27:12\u201318. https:\/\/doi.org\/10.1159\/000121208","journal-title":"Pediatr Neurosurg"},{"issue":"1","key":"7084_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-020-00903-2","volume":"8","author":"S Ryall","year":"2020","unstructured":"Ryall S, Tabori U, Hawkins C (2020) Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun 8(1):30. https:\/\/doi.org\/10.1186\/s40478-020-00903-2","journal-title":"Acta Neuropathol Commun"},{"issue":"6","key":"7084_CR14","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00401-013-1119-8","volume":"125","author":"S Dahiya","year":"2013","unstructured":"Dahiya S, Haydon DH, Alvarado D et al (2013) BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol 125(6):901\u2013910. https:\/\/doi.org\/10.1007\/s00401-013-1119-8","journal-title":"Acta Neuropathol"},{"issue":"1","key":"7084_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0356-1","volume":"12","author":"F Del Bufalo","year":"2014","unstructured":"Del Bufalo F, Carai A, Fig\u00e0-Talamanca L et al (2014) Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent. J Transl Med 12(1):356. https:\/\/doi.org\/10.1186\/s12967-014-0356-1","journal-title":"J Transl Med"},{"issue":"24","key":"7084_CR16","doi-asserted-by":"publisher","first-page":"7303","DOI":"10.1158\/1078-0432.CCR-19-0837","volume":"25","author":"DR Hargrave","year":"2019","unstructured":"Hargrave DR, Bouffet E, Tabori U et al (2019) Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade glioma: a phase I\/IIa study. Clin Cancer Res 25(24):7303\u20137311. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0837","journal-title":"Clin Cancer Res"},{"key":"7084_CR17","doi-asserted-by":"publisher","unstructured":"Nobre L, Zapotocky M, Ramaswamy V, et al. (2020) Outcome of BRAF V600E pediatric gliomas treated with targeted BRAF inhibition. JCO Precis Oncol.4:PO.19.00298. https:\/\/doi.org\/10.1200\/PO.19.00298","DOI":"10.1200\/PO.19.00298"},{"issue":"12","key":"7084_CR18","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","volume":"389","author":"E Bouffet","year":"2023","unstructured":"Bouffet E, Hansford JR, Garr\u00e8 ML et al (2023) Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med 389(12):1108\u20131120. https:\/\/doi.org\/10.1056\/NEJMoa2303815","journal-title":"N Engl J Med"},{"issue":"2","key":"7084_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1158\/1078-0432.CCR-23-1503","volume":"30","author":"MI Barbato","year":"2024","unstructured":"Barbato MI, Nashed J, Bradford D et al (2024) FDA approval summary: dabrafenib in combination with trametinib for BRAFV600E mutation-positive low-grade glioma. Clin Cancer Res 30(2):263\u2013268. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1503","journal-title":"Clin Cancer Res"},{"issue":"7","key":"7084_CR20","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3867","volume":"101","author":"A Ollech","year":"2021","unstructured":"Ollech A, Yalon M, Abebe-Campino G et al (2021) Cutaneous adverse events to targeted therapies and immunotherapies in children: a retrospective study of 103 patients from two tertiary hemato-oncology referral centres. Acta Derm Venereol 101(7):adv00501. https:\/\/doi.org\/10.2340\/00015555-3867","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"7084_CR21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/1758834014566428","volume":"7","author":"SJ Welsh","year":"2015","unstructured":"Welsh SJ, Corrie PG (2015) Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther Adv Med Oncol 7(2):122\u2013136. https:\/\/doi.org\/10.1177\/1758834014566428","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"7084_CR22","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/17425255.2016.1239723","volume":"12","author":"D Rizzo","year":"2016","unstructured":"Rizzo D, Ruggiero A, Amato M et al (2016) BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities. Expert Opin Drug Metab Toxicol 12(12):1397\u20131405. https:\/\/doi.org\/10.1080\/17425255.2016.1239723","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"8","key":"7084_CR23","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1093\/neuonc\/noae074","volume":"26","author":"P O\u2019Hare","year":"2024","unstructured":"O\u2019Hare P, Cooney T, de Blank P et al (2024) Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: a modified Delphi approach to build international consensus-based definitions\u2014International Pediatric Low-Grade Glioma Coalition. Neuro Oncol 26(8):1357\u20131366. https:\/\/doi.org\/10.1093\/neuonc\/noae074","journal-title":"Neuro Oncol"},{"issue":"3","key":"7084_CR24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11060-016-2326-6","volume":"131","author":"J Zhang","year":"2017","unstructured":"Zhang J, Yao TW, Hashizume R, Hariono S (2017) Combined BRAFV600E and MEK blockade for BRAFV600E mutant gliomas. J Neurooncol 131(3):495\u2013505. https:\/\/doi.org\/10.1007\/s11060-016-2326-6","journal-title":"J Neurooncol"},{"issue":"6","key":"7084_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1470-2045(11)70057-1","volume":"12","author":"MJ Van den Bent","year":"2011","unstructured":"Van den Bent MJ, Wefel JS, Schiff D et al (2011) Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 12(6):583\u2013593. https:\/\/doi.org\/10.1016\/S1470-2045(11)70057-1","journal-title":"Lancet Oncol"},{"issue":"1","key":"7084_CR26","doi-asserted-by":"publisher","DOI":"10.2217\/cns-2018-0016","volume":"8","author":"UN Chukwueke","year":"2019","unstructured":"Chukwueke UN, Wen PY (2019) Use of the response assessment in neuro-oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol 8(1):CNS28. https:\/\/doi.org\/10.2217\/cns-2018-0016","journal-title":"CNS Oncol"},{"issue":"9","key":"7084_CR27","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/pbc.24526","volume":"60","author":"KE Warren","year":"2013","unstructured":"Warren KE, Poussaint TY, Vezina G et al (2013) Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Pediatr Blood Cancer 60(9):1397\u20131401. https:\/\/doi.org\/10.1002\/pbc.24526","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"7084_CR28","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/CMR.0000000000000456","volume":"28","author":"F Dimitriou","year":"2018","unstructured":"Dimitriou F, Zindler J, Mangana J et al (2018) Sarcoid-like reactions in patients receiving modern melanoma treatment. Melanoma Res 28(3):230\u2013236. https:\/\/doi.org\/10.1097\/CMR.0000000000000456","journal-title":"Melanoma Res"},{"issue":"11","key":"7084_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30619","volume":"70","author":"M Wilhelmsson","year":"2023","unstructured":"Wilhelmsson M, Chun FJ, Yeung RSM et al (2023) <article-title update=\"added\">Sarcoid\u2010like reaction in a child following prolonged therapeutic exposure to dabrafenib and trametinib for BRAF V600E mutated hypothalamic\/chiasmatic glioma. Pediatr Blood Cancer 70(11):e30619. https:\/\/doi.org\/10.1002\/pbc.30619","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"7084_CR30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11060-024-04857-2","volume":"171","author":"C Cacciotti","year":"2025","unstructured":"Cacciotti C, Tabori U, Hawkins C, Bennett J (2025) Targeting the RAS\/MAPK pathway in children with glioma. J Neurooncol 171(2):265\u2013277. https:\/\/doi.org\/10.1007\/s11060-024-04857-2","journal-title":"J Neurooncol"},{"issue":"9","key":"7084_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138245","volume":"10","author":"N D\u2019Haene","year":"2015","unstructured":"D\u2019Haene N, Le Mercier M, De N\u00e8ve N et al (2015) Clinical validation of targeted next generation sequencing for colon and lung cancers. PLoS One 10(9):e0138245. https:\/\/doi.org\/10.1371\/journal.pone.0138245","journal-title":"PLoS One"}],"container-title":["Child's Nervous System"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-025-07084-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00381-025-07084-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00381-025-07084-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:17:16Z","timestamp":1770815836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00381-025-07084-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["7084"],"URL":"https:\/\/doi.org\/10.1007\/s00381-025-07084-w","relation":{},"ISSN":["0256-7040","1433-0350"],"issn-type":[{"value":"0256-7040","type":"print"},{"value":"1433-0350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"5 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"429"}}